

Cardiac safety profile of bleximenib: Insights from EHA 2026

Cardiac safety analyses of cAMeLot-1 and ALE1002 trial data: treatment-emergent QTc prolongation; exposure–response analyses; difference in QTcF across time points.

TRIAL DESIGNS

